文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

作者信息

Tung Nadine M, Zakalik Dana, Somerfield Mark R

机构信息

Beth Israel Deaconess Medical Center, Boston, MA.

Beaumont Health, Royal Oak, MI.

出版信息

J Clin Oncol. 2021 Sep 10;39(26):2959-2961. doi: 10.1200/JCO.21.01532. Epub 2021 Aug 3.

DOI:10.1200/JCO.21.01532
PMID:34343058
Abstract
摘要

相似文献

[1]
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

J Clin Oncol. 2021-9-10

[2]
Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2022-11-20

[3]
Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023-2-20

[4]
Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2022-9-10

[5]
Testing for Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023-6-20

[6]
Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.

J Clin Oncol. 2022-1-20

[7]
Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2024-6-20

[8]
Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2022-5-20

[9]
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.

Breast. 2022-12

[10]
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.

J Clin Oncol. 2024-4-20

引用本文的文献

[1]
Multiple drug resistance caused by germline mutation of exon 27 of BRCA2 gene in triple-negative breast cancer: a case report and literature review.

Front Oncol. 2025-6-19

[2]
Therapeutic advances and application of PARP inhibitors in breast cancer.

Transl Oncol. 2025-7

[3]
Potential candidates for adjuvant olaparib treatment in operable breast cancer patients with germline BRCA1/2 pathogenic variants after neoadjuvant chemotherapy.

Breast Cancer Res Treat. 2025-6

[4]
Recent advancements in nanomaterial-based biosensors for diagnosis of breast cancer: a comprehensive review.

Cancer Cell Int. 2025-2-18

[5]
ChatGPT's Agreement with the Recommendations from the 18th St. Gallen International Consensus Conference on the Treatment of Early Breast Cancer.

Cancers (Basel). 2024-12-13

[6]
The Tumour Microenvironment and Epigenetic Regulation in Pathogenic Variant-Associated Breast Cancers.

Cancers (Basel). 2024-11-21

[7]
Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a mutation.

Oncol Lett. 2024-11-20

[8]
Quantitative Determination of Endoplasmic Reticulum Viscosity during Immunogenic Cell Death by a Theranostic Rhenium Complex.

Chem Biomed Imaging. 2023-10-12

[9]
BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.

Br J Cancer. 2024-11

[10]
Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.

J Manag Care Spec Pharm. 2024-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索